Oxaliplatin-induced neurotoxicity;Neurotoxicidad inducida por oxaliplatino

Atencion Farmaceutica

Volumn 13, Issue 5, 2011, Pages 280-293

  Esteban Sánchez, Marta ^a   Hurtado Gómez, María Fe ^a   Gallardo Anciano, Jara ^a   Alfaro Olea, Ascensión ^a  

^a HOSPITAL SAN PEDRO   (Spain)

Author keywords

Adverse effects; Colorectal cancer; Neurotoxicity; Oxaliplatin; Prevention

Indexed keywords

OXALIPLATIN;

ARTICLE; COLD EXPOSURE; COLORECTAL CANCER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSESTHESIA; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHY; NEUROTOXICITY; OBSERVATIONAL STUDY; PREVALENCE; RETROSPECTIVE STUDY;

EID: 84856740007     PISSN: 11397357     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gogoco KO, Haller DG, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003; 21: 2904-11. (Pubitemid 46621840)
2. Ficha técnica de Oxaliplatino. Centro de Informacion Online de Medicamentos [Base de datos en Internet]. Madrid: Agencia Española del Medicamento y Productos Sanitarios [Acceso 10 mayo 2010]. Disponible en: http://www.agemed.es.
3. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity. How and why?. Crit Rev Oncol Hematol 2006; 59: 159-68.
4. Broomand A, Jerremalm E, Yachnin J, Ehrsson H, Elinder F. Oxaliplatin neurotoxicity - no general ion channel surface-charge effect. Biomed Central [Revista en Internet] 2009; 8. Disponible en http://www.jnrbm.eom/content/8/12
5. Cersosimo RJ. Oxaliplatin-Associated Neuropathy: A Review. Ann Pharmacother 2005; 39: 128-35. (Pubitemid 40052388)
6. Grothey A. Oxaliplatin-Safety Profile: Neurotoxicity. Scmin Oncol 2003; 30 (4 Supl 15): 5-13.
7. Maindrault-Goebel F, Louvet C, Carola E, et al. Oxaliplatin reintroduction in patients pretreated with leucovorin (LV), 5-Fu and oxaliplatin for metastadic colorectal cancer. A Gercor study. Proc Am Soc Clin Oncol 2000; 19: 255a (abs 990).
8. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 2001; 12: 421-2. (Pubitemid 32288702)
9. Mariani G, Garronne O, Granetto C, et al. Oxaliplatin induced neuropathy: could gabapentin be the answer?. Proc Am Soc Clin Oncol 2000; 19: 609a (abs 2397).
10. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. Biomed Central [Revista en Internet] 2005; 5. Disponible en http://www.biomedcentral.eom/1471- 2407/5/116 [Consulta: 4/3/2010].
11. Mas Morey P, Nigorra Caro M, Cholvi Llovell M, Nicolás Picó J, March Frontera C, Vilanova Boltó M. Neurotoxicidad asociada a oxaliplatino con dos esquemas diferentes de quimioterapia en pacientes diagnosticados de cáncer colorrectal. Revista de abstracts del 55 Congreso de la SEFH. Madrid 2010.
12. Vergniory Trueba OA, Zapico García I, González Sanchez N, Iglesias García MT. Manejo de la neurotoxicidad inducida por oxaliplatino. Revista de abstracts del 55 Congreso de la SEFH. Madrid 2010.
13. Guo-Qiang W, De-Sen W, Zhi-Wei Z, Zhi-Zhong P, Gong C, Zhen-Hai L et al. Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis. Chin J Cancer 2007; 26: 411-4.